PMID: 3383718Jan 1, 1988Paper

Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus

Developmental Pharmacology and Therapeutics
G L KearnsD L Nelson

Abstract

We evaluated serum protein binding of phenytoin and lidocaine, the extent of albumin and hemoglobin glycation, and alpha-1-acid glycoprotein concentrations in 47 children and adolescents (9-17 years) with type I diabetes mellitus (DM). Serum was incubated with phenytoin (n = 47) and lidocaine (n = 32) to yield total concentrations of 19.4 +/- 1.34 and 4.6 +/- 0.5 mg/l, respectively. A serum ultrafiltrate was prepared from an aliquot of each sample by membrane centrifugation. Total and free concentrations of phenytoin (free fraction 8.3 +/- 1.0%) and lidocaine (free fraction 25.8 +/- 11.6%) were determined using a fluorescence polarization immunoassay technique. A linear relationship (r = 0.63, p = 0.0001, y = 40.1 + [-0.2x]) was also found between the alpha-1-acid glycoprotein concentration (68.5 +/- 20.9 mg%, range 47.2-134.7 mg%) and lidocaine-free fraction (n = 32). No relationship existed between the extent of glycated albumin and the lidocaine-free fraction, in contrast to the linear correlation (r = 0.49, p = 0.0005, y = 3.7 + 0.4x) found between the extent of glycated albumin and the free fraction of phenytoin in serum (n = 47). A similar correlation (r = 0.49, p = 0.014, y = 3.7 + 0.3x) was found between glycated albumi...Continue Reading

Citations

Jul 17, 1998·Biomedical Chromatography : BMC·K KoizumiT Hanai
Jan 1, 1993·European Journal of Clinical Pharmacology·J DoucetN Moore
Jun 7, 2012·Clinical Pharmacokinetics·Miroslav DostalekMartina Puzanovova
Jan 9, 2014·Journal of Diabetes and Metabolic Disorders·Alok S TripathiAnil V Chandewar
Jun 7, 2002·AAPS PharmSci·Patrick J McNamara, Jane Alcorn
Dec 21, 2010·Biochimie·Philippe Rondeau, Emmanuel Bourdon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.